BeiGene Reports Outcomes of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia
Click on this link to read complete press release/ post|Ref: BeiGene|Image: BeiGene.
The P-III SEQUOIA trial examining effectiveness & & safety of Brukinsa vs bendamustine + rituximab (B+R) in clients with treatment-naïve CLL or SLL whose growth did not show the deletion of chromosome 17p13.1 (del [17p]
The interim analysis of trial satisfied its 1EPs @ mean follow-up of 25.8 mos, demonstrates improvement in PFS as examined by IRC. The therapy was well-tolerated & & constant with its recognized security profile
Brukinsa (zanubrutinib) is a BTK inhibitor, presently being assessed in numerous medical studies worldwide as a monothx. or in mix with other treatments targeting B cell malignancies. The company plans to speak with worldwide regulative authorities